

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Serial No.:	<b>09/436,347</b>	Group Art Unit:	1643
Confirmation No.:	6491	Examiner:	A.M. Harris
Filed:	9 November 1999		
Inventor:	Christine A. WHITE <i>et al.</i>		
For:	Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies (as amended)		

Mail Stop **Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In compliance with the requirements and provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicant cites the information listed on the Form PTO-1449 that accompanies this paper and the pending patent applications identified below. Applicant does not represent that a search has been conducted or that the cited documents are prior art against the claims in this application.

Copies of the cited non-U.S. patent documents, with the exception of items D62, D101, D153, D204, and D257 accompany this submission. The latter documents were submitted as attachments to the RCE and amendment filed on 7 August 2006 and are not duplicated here.

This disclosure statement is filed under the provisions of 37 C.F.R. § 1.97(b)(4) prior to the mailing date of an action on the merits following a Request for Continued Examination under 37 C.F.R. § 1.114. Applicant believes that no fee is due in connection with this disclosure statement. However, should any additional fee be required to render this paper timely or proper, applicant requests that the Director charge the required fee to our Deposit Account No. 18-1260.

**Copending patent applications**

In addition to the information cited on the Form PTO-1449 that accompanies this paper, applicant directs the examiner's attention to the commonly-owned pending U.S. patent applications listed below.

<b>Serial No.</b>	<b>Filing Date</b>	<b>First Inventor</b>
09/628,187	28 Jul 2000	White
09/762,587	06 Sep 2001	Grillo-López
09/911,692	25 Jul 2001	Anderson
09/911,703	25 Jul 2001	Anderson
10/096,964	14 Mar 2002	Anderson
10/196,732	17 Jul 2002	Grillo-López
10/238,681	11 Sep 2002	Anderson
10/440,186	19 May 2003	Grillo-López
10/850,712	21 May 2004	Grillo-López

Respectfully submitted,

/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347  
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN LLP  
1501 K Street, N.W.  
Washington, DC 20005

tel. (202) 736-8818  
fax (202) 736-8711

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No. 27693-01201	Serial No: <b>09/ 436,347</b>
	Inventor(s): Christine WHITE <i>et al.</i>	Examiner: A.M. HARRIS
	Filed: 9 November 1999	Art Unit: 1643

### U.S. PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB.	FILING DATE
	<b>D1</b>	Re 38,008	25 Feb 2003	Abrams			
	<b>D2</b>	4,831,175	16 May 1989	Gansow			
	<b>D3</b>	4,975,278	4 Dec 1990	Senter			
	<b>D4</b>	5,099,069	24 Mar 1992	Gansow			
	<b>D5</b>	5,124,471	23 Jun 1992	Gansow			
	<b>D6</b>	5,246,692	21 Sep 1993	Gansow			
	<b>D7</b>	5,286,850	15 Feb 1994	Gansow			
	<b>D8</b>	5,439,665	8 Aug 1995	Hansen			
	<b>D9</b>	5,460,785	24 Oct 1995	Rhodes			
	<b>D10</b>	5,595,721	21 Jan 1997	Kaminski			
	<b>D11</b>	5,648,267	15 Jul 1997	Reff			
	<b>D12</b>	5,677,180	14 Oct 1997	Robinson			
	<b>D13</b>	5,686,072	11 Nov 1997	Uhr			
	<b>D14</b>	5,691,320	25 Nov 1997	van Borstel			
	<b>D15</b>	5,693,780	2 Dec 1997	Newman			
	<b>D16</b>	5,721,108	24 Feb 1998	Robinson			
	<b>D17</b>	5,726,023	10 Mar 1998	Cheever			
	<b>D18</b>	5,843,398	1 Dec 1998	Kaminski			
	<b>D19</b>	6,015,542	18 Jan 2000	Kaminski			
	<b>D20</b>	6,090,365	18 Jul 2000	Kaminski			
	<b>D21</b>	6,120,767	19 Sep 2000	Robinson			
	<b>D22</b>	6,287,537 B1	11 Sep 2001	Robinson			

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 1 OF 23</b>

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No. 27693-01201	Serial No: <b>09/ 436,347</b>
	Inventor(s): Christine WHITE <i>et al.</i>	Examiner: A.M. HARRIS
	Filed: 9 November 1999	Art Unit: 1643

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB.	FILING DATE
	<b>D23</b>	6,565,827 B1	20 May 2003	Kaminski			
	<b>D24</b>	6,652,852 B1	25 Nov 2003	Robinson			
	<b>D25</b>	6,893,625 B1	17 May 2005	Robinson			
	<b>D26</b>	2002/ 0009444 A1	24 Jan 2002	Grillo-López			
	<b>D27</b>	2002/ 0197255 A1	26 Dec 2002	Anderson			
	<b>D28</b>	2003/ 0021781 A1	30 Jan 2003	Anderson			
	<b>D29</b>	2003/ 0026804 A1	24 Feb 2003	Grillo-López			
	<b>D30</b>	2003/ 0082172 A1	1 May 2003	Anderson			
	<b>D31</b>	2003/ 0095963 A1	22 May 2003	Anderson			
	<b>D32</b>	2003/ 0206903 A1	6 Nov 2003	Grillo-López			
	<b>D33</b>	2004/ 0167319 A1	26 Aug 2004	Teeling			
	<b>D34</b>	2004/ 0213784 A1	28 Oct 2004	Grillo-López			
	<b>D35</b>	2004/ 056312 A2	8 Jul 2004	Adams			
	<b>D36</b>	2005/ 0163708 A1	28 July 2005	Robinson			
	<b>D37</b>	2005/ 0186205 A1	25 Aug 2005	Anderson			
	<b>D38</b>	2006/ 0034835 A1	16 Feb 2006	Adams			

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 2 OF 23</b>

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No. 27693-01201	Serial No: <b>09/ 436,347</b>
	Inventor(s): Christine WHITE <i>et al.</i>	Examiner: A.M. HARRIS
	Filed: 9 November 1999	Art Unit: 1643

### FOREIGN PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	COUNTRY	CLASS	SUB.	TRANSLATION	
	<b>D39</b>	0 125 023 A1	14 Nov 1994	EP				
	<b>D40</b>	0 173 494 A2	5 May 1986	EP				
	<b>D41</b>	0 274 394 A2	13 Jul 1988	EP				
	<b>D42</b>	0 451 216 B1	24 Jan 1996	EP				
	<b>D43</b>	0 669 836 B1	7 Mar 1996	EP				
	<b>D44</b>	0 682 040 A1	15 Nov 1995	EP				
	<b>D45</b>	0 752 248 A1	8 Jan 1997	EP				
	<b>D46</b>	87/ 02671 A1	7 May 1987	WO				
	<b>D47</b>	88/ 04936 A1	14 Jul 1988	WO				
	<b>D48</b>	89/ 00999 A1	9 Feb 1989	WO				
	<b>D49</b>	91/ 04320 A1	4 Apr 1991	WO				
	<b>D50</b>	92/ 07466 A1	14 May 1992	WO				
	<b>D51</b>	93/ 02108 A1	4 Feb 1993	WO				
	<b>D52</b>	94/11026 A2	26 May 1994	WO				
	<b>D53</b>	00/ 09160 A1	24 Feb 2000	WO				
	<b>D54</b>	00/ 27428 A1	18 May 2000	WO				
	<b>D55</b>	00/ 27433 A1	18 May 2000	WO				
	<b>D56</b>	01/ 10460 A1	15 Feb 2001	WO				
	<b>D57</b>	2004/ 056312 A2	8 Jul 2004	WO				

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 3 OF 23</b>

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

### OTHER DOCUMENTS

INITIAL	INDEX	CITATION
	<b>D58</b>	Adams R.A. <i>Cancer Res.</i> 27: 2479-82, 1967. Formal discussion: the role of transplantation in the experimental investigation of human leukemia and lymphoma.
	<b>D59</b>	Adams R.A. et al. <i>Cancer Res.</i> 28(6): 1121-25, 1968. Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2.
	<b>D60</b>	Alas S. et al. <i>Clin. Cancer Res.</i> 7(3): 709-23, 2001. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
	<b>D61</b>	Alas S. et al. <i>Clin. Cancer Res.</i> 8(3): 836-45, 2002. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
	<b>D62</b>	Almasri N.M. et al. <i>Am. J. Hematol.</i> 40: 259-63, 1992. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia.
	<b>D63</b>	Anderson D.R. et al. <i>Biochem. Soc. Trans.</i> 25(2): 705-08, 1997. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
	<b>D64</b>	Anderson D.R. et al. Second IBC Int'l. Conference on Antibody Engineering, San Diego, 16-18 December 1991. Immunoreactivity and effector function associated with a chimeric anti-CD20 antibody (abstract of presentation).
	<b>D65</b>	Anderson K.C. et al. <i>Blood</i> 63(6): 1424-33, 1984. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation.
	<b>D66</b>	Anderson K.C. et al. <i>Blood</i> 69(2): 597-604, 1987. Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow.
	<b>D67</b>	Appelbaum F.R. <i>Hem. Onc. Clin. N. Amer.</i> 5(5): 1013-25, 1991. Radiolabeled monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
	<b>D68</b>	Armitage J.O. et al. <i>Cancer</i> 50: 1695-1702, 1982. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 4 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D69</b>	Armitage J.O. et al. <i>J. Clin. Oncol.</i> 16(8): 2780-95, 1998. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.
	<b>D70</b>	Azogui O. et al. <i>J. Immunol.</i> 131: 1205-08, 1983. Inhibition of IL-2 production after human allogeneic bone marrow transplantation.
	<b>D71</b>	Badger C.C. et al. <i>Cancer Res.</i> 46: 6223-28, 1986. Experimental radioimmunotherapy of murine lymphoma with <sup>131</sup> I-labeled anti-T-cell antibodies.
	<b>D72</b>	Berinstein N.L. et al. <i>Ann. Oncol.</i> 9: 995-1001, 1998. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.
	<b>D73</b>	Beychok S. (in) <i>Cells of Immunoglobulin Synthesis</i> , B. Pernis et al., eds. New York: Academic Press, 1979, 69-88. Comparative aspects of <i>in vitro</i> and cellular assembly of immunoglobulins.
	<b>D74</b>	Bhan A.K. et al. <i>J. Exp. Med.</i> 154: 737-49, 1981. Stages of B cell differentiation in human lymphoid tissue.
	<b>D75</b>	<i>Biogen Idec Inc. v. Corixa Corp.</i> , Case No. 01-CV-1637 IEG (RBB), Order Granting Patentees' Motion for Reconsideration, <i>etc.</i> (S.D.Cal., Jan. 22, 2004).
	<b>D76</b>	<i>Biogen Idec Inc. v. Corixa Corp.</i> , Case No. 01-CV-1637 IEG (RBB), Stipulation of Dismissal of Claims and Counterclaims with Prejudice and Order (S.D.Cal., May 13, 2004).
	<b>D77</b>	Bosly A. et al. <i>Nouv. Rev. Fr. Hematol.</i> 32(1): 13-16, 1990. Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.
	<b>D78</b>	Boulianne G.L. et al. <i>Nature</i> 312: 643-46, 1984. Production of functional chimaeric mouse/human antibody.
	<b>D79</b>	Brunner K.T. et al. <i>Immunology</i> 14(2): 181-96, 1968. Quantitative assay of the lytic action of immune lymphoid cells on <sup>51</sup> Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.
	<b>D80</b>	Buchsbaum D.J. et al. <i>Cancer Res.</i> 50: 993s-999s, 1990. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 5 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D81</b>	Buchsbaum D.J. et al. <i>Cancer Res.</i> 52: 637-642, 1992. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.
	<b>D82</b>	Buchsbaum D.J. et al. <i>Cancer Res.</i> 52: 6476-81, 1992. Therapy with unlabeled and <sup>131</sup> I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
	<b>D83</b>	Buchsbaum D.J. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 18: 1033-41, 1990. A comparison of <sup>131</sup> I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts.
	<b>D84</b>	Buchsbaum D.J. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 25(4): 629-38, 1993. Comparison of <sup>131</sup> I- and <sup>90</sup> Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts.
	<b>D85</b>	Byrd J.C. et al. <i>Blood</i> 92(10 Suppl. 1): 106a, abst. no. 432, Nov. 1998. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid tumor lysis.
	<b>D86</b>	Byrd J.C. et al. <i>J. Clin. Oncol.</i> 19(8): 2153-64, 2001. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
	<b>D87</b>	Caligiuri M.A. <i>Semin. Oncol.</i> 20(6 Suppl 9): 3-10, 1993. Low-dose interleukin-2 therapy: rationale and potential clinical applications.
	<b>D88</b>	Caligiuri M.A. et al. <i>J. Clin. Oncol.</i> 9(12): 2110-19, 1991. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.
	<b>D89</b>	Caligiuri M.A. et al. <i>J. Clin. Invest.</i> 91(1): 123-32, 1993. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
	<b>D90</b>	Calvert J.E. et al. <i>Semin. Hematol.</i> 21(4): 226-243, 1984. Cellular events in the differentiation of antibody-secreting cells.
	<b>D91</b>	Carrasquillo J.A. et al. <i>J. Nucl. Med.</i> 26: 67, abst. no. 276, 1985. Improved imaging of metastatic melanoma with high dose 9.2.27 In-111 monoclonal antibody.
	<b>D92</b>	Cayeux S. et al. <i>Blood</i> 74(6): 2270-77, 1989. T-cell ontogeny after autologous bone marrow transplantation: failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4- and CD8+ cells even in the presence of exogenous IL-2.
	<b>D93</b>	Chen J.J. et al. <i>J. Immunol.</i> 143(3): 1053-57, 1989. Tumor idiotypic vaccines. VI. Synergistic anti-tumor effects with combined "internal image" anti-idiotypes and chemotherapy.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 6 OF 23	



<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D94</b>	Chinn P. et al. <i>Proc. Ann. Mtg. Am. Assn. Cancer Res.</i> 33: 337, abst. no. 2012, 1992. Production and characterization of radiolabeled anti-CD20 monoclonal antibody: potential application to treatment of B-cell lymphoma.
	<b>D95</b>	Chinn P.C. et al. <i>Int. J. Oncol.</i> 15(5): 1017-25, Nov. 1999. Preclinical evaluation of <sup>90</sup> Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
	<b>D96</b>	Chinn P.C. et al. <i>Proc. Ann. Mtg. Am. Assn. Cancer Res.</i> 40: 574, abst. no. 3786, 1999. A <sup>90</sup> Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium.
	<b>D97</b>	Chomezynki P. et al. <i>Anal. Biochem.</i> 162: 156-59, 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
	<b>D98</b>	Clark E.A. et al. <i>J. Cell. Biochem.</i> (Suppl. 9A): 63, 1985. Anti-Bp35 antibody induces human B cell proliferation: implications for <i>in vivo</i> immunotherapy.
	<b>D99</b>	Clark E.A. et al. <i>Proc. Natl. Acad. Sci. USA</i> 82(6): 1766-70, 1985. Role of the Bp35 cell surface polypeptide in human B-cell activation.
	<b>D100</b>	Classon B.J. et al. <i>J. Exp. Med.</i> 169(4): 1497-1502, 1989. The primary structure of the human leukocyte antigen CD37, a species homologue of the rat MRC OC-44 antigen.
	<b>D101</b>	Cogliatti S.B. et al. <i>Sw. Med. Weekly</i> 192: 607-17, 2002. Who is <i>WHO</i> and what was <i>REAL</i> ?
	<b>D102</b>	Cohen Y. et al. <i>Leuk. Lymphoma</i> 43(7): 1485-87, 2002. Large B-cell lymphoma manifesting as an invasive cardiac mass: sustained local remission after combination of methotrexate and rituximab.
	<b>D103</b>	Coiffier B. et al. <i>Blood</i> 92(6): 1927-32, 1998. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
	<b>D104</b>	Coiffier B. et al. <i>N. Engl. J. Med.</i> 346(4): 235-42, 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
	<b>D105</b>	Coleman M. et al. <i>Blood</i> 102(11 pt.1): 29a, abst. no. 29, 2003. The BEXXAR® therapeutic regimen (tositumomab and Iodine I-131 tositumomab) produced durable complete remissions in heavily pretreated patients with non-Hodgkin's lymphoma (NHL), rituximab-relapsed/refractory disease, and rituximab-naïve disease.
	<b>D106</b>	Colombat P. et al. <i>Blood</i> 97: 101-06, 2001. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
	<b>D107</b>	Cope. <i>Oncology</i> 8(4): 100, 1994. Antibody shows promise in treating B-cell lymphoma.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 7 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D108</b>	Curti B.D. <i>Crit. Rev. Oncol. Hematol.</i> 14(1): 29-39, Feb. 1993. Physical barriers to drug delivery in tumors.
	<b>D109</b>	Czuczman M. et al. <i>Blood</i> 94(10 Suppl. 1): 99a, abst. no. 432, 1999. Rituximab/CHOP chemoimmunotherapy in patients (PTS) with low grade lymphoma (LG/F NHL): progression free survival (PFS) after three years (median) follow-up.
	<b>D110</b>	Czuczman M.S. et al. <i>J. Clin. Oncol.</i> 17(1): 268-76, Jan. 1999. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
	<b>D111</b>	Davis T. et al. <i>Blood</i> 90(10 Suppl. 1): 509a, abst no. 2269 (Nov. 1997). Retreatments with RITUXAN™ (Rituximab, Idec-C2B8) have significant efficacy, do not cause HAMA, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL).
	<b>D112</b>	Davis T. et al. <i>Proc. Ann. Mtg. ASCO</i> 17: abst. no. 39 (May 1998). Combination immunotherapy of low grade or follicular (LG/F) non-Hodgkin's lymphoma (NHL) with rituximab and alpha interferon: interim analysis.
	<b>D113</b>	Davis T.A. et al. <i>Blood</i> 86(10 Suppl. 1): 237a, abst. no. 1080, 1995. <sup>90</sup> Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma.
	<b>D114</b>	Davis T.A. et al. <i>Blood</i> 92(10 Suppl. 1): 414a, abst. no. 1710, Nov. 1998. Rituximab: phase II (PII) retreatment (ReRx) study in patients (PTS) with low grade or follicular (LG/F) NHL.
	<b>D115</b>	Davis T.A. et al. <i>Blood</i> 92(10 Suppl. 1): 414a, abst. no. 1711, Nov. 1998. Rituximab: first report of a phase II (PII) trial in NHL patients (PTS) with bulky disease.
	<b>D116</b>	Davis T.A. et al. <i>Clin. Cancer Res.</i> 5(3): 611-15, 1999. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
	<b>D117</b>	Davis T.A. et al. <i>J. Clin. Oncol.</i> 17(6): 1851-57, 1999. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
	<b>D118</b>	Davis T.A. et al. <i>Proc. Ann. Mtg. Amer. Assn. Cancer Res.</i> 39: 435, abst. no. 2964, 1998. Therapy of B cell lymphoma with anti-CD20 can result in relapse with loss of CD20 expression.
	<b>D119</b>	Demidem A. et al. <i>Cancer Biother. Radiopharm.</i> 12(3): 177-86, 1997. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
	<b>D120</b>	DeNardo G.L. et al. <i>Cancer Res.</i> 50(3 Suppl.): 1014s-1016s, 1990. Fractionated radioimmunotherapy of B-cell malignancies with <sup>131</sup> I-Lym-1.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 8 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D121</b>	DeNardo G.L. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 11(2): 335-48, 1985. Requirements for a treatment plan in system for radioimmunotherapy.
	<b>D122</b>	DeNardo S.J. et al. <i>Antibody Immunoconj. Radiopharm.</i> 1(1): 17-33, 1988. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody.
	<b>D123</b>	DeNardo S.J. et al. <i>Cancer</i> 73(3 Suppl.): 1023-32, 1994. The biologic window for chimeric L6 radioimmunotherapy.
	<b>D124</b>	Di Gaetano N. et al. <i>Br. J. Haematol.</i> 114(4): 800-09, 2001. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
	<b>D125</b>	Dickson S. <i>Gen. Engr. News</i> 5(3): 1, March 1985. Scientists produce chimeric monoclonal Abs.
	<b>D126</b>	Dillman R.O. <i>J. Clin. Oncol.</i> 12(7): 1497-1515, 1994. Antibodies as cytotoxic therapy.
	<b>D127</b>	Eary J.F. et al. <i>J. Nuc. Med.</i> 31(8): 1257-68, 1990. Imaging and treatment of B-cell lymphoma.
	<b>D128</b>	Einfeld D.A. et al. <i>EMBO J.</i> 7: 711-17, 1988. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.
	<b>D129</b>	Endo K. <i>Jpn. J. Cancer Chemother.</i> 26: 744-48, 1999. Current status of nuclear medicine in Japan.
	<b>D130</b>	Flinn I.W. et al. <i>Blood</i> 92(10 Suppl. 1): 648a, abst. no. 2678, Nov. 1998. In vivo purging and adjuvant immunotherapy with rituximab during PBSC transplant for NHM [sic].
	<b>D131</b>	Foran J.M. et al. <i>J. Clin. Oncol.</i> 18: 317-24, 2000. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
	<b>D132</b>	Freedman A.S. et al. <i>J. Clin. Oncol.</i> 8: 784-91, 1990. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse.
	<b>D133</b>	Friedberg J.W. et al. <i>Expert Rev. Anticancer Ther.</i> 4(1): 18-26, 2004. Iodine-131 tositumomab (Bexxar®): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
	<b>D134</b>	Golay J.T. et al. <i>J. Immunol.</i> 135(6): 3795-801, 1985. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 9 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D135</b>	Goldenberg D.M. et al. <i>J. Clin. Oncol.</i> 9(4): 548-64, 1991. Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies.
	<b>D136</b>	Gordon L.I. et al. <i>Blood</i> 94(10 Suppl. 1): 91a, abst. no. 396, 1999. ZEVALIN™ (IDEC-Y2B8) radioimmunotherapy of rituximab refractory follicular non-Hodgkin's lymphoma (NHL): interim results.
	<b>D137</b>	Gordon L.I. et al. <i>J. Immunother.</i> 22(5): 459, 1999. Update on IDEC-Y2B8 (ZEVALIN™) radioimmunotherapy of B-cell NHL.
	<b>D138</b>	Greenberger J.S. et al. <i>Cancer Res.</i> 45(2): 758-67, 1985. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture.
	<b>D139</b>	Greiner J.W. et al. <i>Science</i> 235(4791): 895-98, 1987. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo.
	<b>D140</b>	Grillo-López A.J. IBC Int'l. Conference on Antibody Engineering, La Jolla, December 1994. IDEC-C2B8 chimeric antibody and IDEC-Y2B8 radiolabeled antibody phase I and II studies in patients with non-Hodgkin's lymphoma (abstract of presentation).
	<b>D141</b>	Grillo-López A.J. et al. <i>Ann. Oncol.</i> 7(3 Suppl.): 57, abst. no. 195, 1996. Treatment (rx) of relapsed non-Hodgkin's lymphoma (NHL) using the 90-yttrium (90-Y) labeled anti-CD20 monoclonal antibody (MAB) IDEC-Y2B8: a phase I clinical trial (PI CT).
	<b>D142</b>	Grillo-López A.J. et al. <i>Antibody Immunoconj. Radiopharm.</i> 8: 60, abst. no. 10, 1995. Treatment options for patients with relapsed low-grade or follicular lymphoma: the role of IDEC-C2B8.
	<b>D143</b>	Grillo-López A.J. et al. <i>Blood</i> (86(10 Suppl. 1): 55a, abst. no. 207, 1995. Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma.
	<b>D144</b>	Grillo-López A.J. et al. <i>Br. J. Haematol.</i> 93(Suppl. 2): 283, abst. no. 1072, 1996. IDEC-C2B8 chimeric anti-CD20 antibody (MAB): safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL).
	<b>D145</b>	Grossbard M.L. et al. <i>Blood</i> 80(4): 863-78, 1992. Monoclonal antibody-based therapies of leukemia and lymphoma.
	<b>D146</b>	Gura T. <i>Science</i> 278: 1041-42, 1997. Systems for identifying new drugs are often faulty.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 10 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No. 27693-01201	Serial No: 09/ 436,347
	Inventor(s): Christine WHITE <i>et al.</i>	Examiner: A.M. HARRIS
	Filed: 9 November 1999	Art Unit: 1643

INITIAL	INDEX	CITATION
	<b>D147</b>	Hagenbeek A. et al. <i>J. Clin. Oncol.</i> 16(1): 41-47, 1998. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
	<b>D148</b>	Hainsworth J.D. et al. <i>Blood</i> 95: 3052-56, 2000. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.
	<b>D149</b>	Harris N.L. et al. <i>Blood</i> 54(5): 1361-92, 1994. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
	<b>D150</b>	Harris N.L. et al. <i>J. Clin. Oncol.</i> 17(12): 3835-49, 1999. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997.
	<b>D151</b>	Hartwell L.H. et al. <i>Science</i> 278: 1064-68, 1997. Integrating genetic approaches into the discovery of anticancer drugs.
	<b>D152</b>	Hekman A. et al. <i>Ann. Rept. Netherlands Cancer Inst., Amsterdam</i> , pages 47-48, 1993. Immunotherapy.
	<b>D153</b>	Herold M. et al. <i>Ann. Hematol.</i> 79: 332-335, 2000. Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab.
	<b>D154</b>	Hiddemann W. et al. <i>Blood</i> 88(11): 4085-89, 1996. Lymphoma classification—the gap between biology and clinical management is closing.
	<b>D155</b>	Hooijberg E. et al. <i>Cancer Res.</i> 55: 2627-34, 1995. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
	<b>D156</b>	Horning S.J. et al. <i>Blood</i> 100(11 part 1): 357a, abst. no. 1385, 2002. Rituximab treatment failures: tositumomab and Iodine I 131 tositumomab (Bexxar®) can produce meaningful durable responses.
	<b>D157</b>	IDEC Pharmaceuticals Corp., U.S. Securities and Exchange Commission Form S-1 Registration Statement, 1991.
	<b>D158</b>	IDEC Pharmaceuticals Corp. and Genentech, Inc., Product insert for RITUXAN® approved by U.S. Food and Drug Administration on 26 November 1997.
	<b>D159</b>	International Non-Hodgkin's Lymphoma Prognostic Factors Project. <i>N. Engl. J. Med.</i> 329(14): 987-94, 1993. A predictive model for aggressive non-Hodgkin's lymphoma.
	<b>D160</b>	Jain R.K. <i>Sci. Am.</i> 271(1): 58-65, 1994. Barriers to drug delivery in solid tumors.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 11 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D161</b>	Janakirman N. et al. <i>Blood</i> 92(10 Suppl. 1): 337a, abst. no. 1384, Nov. 1998. Rituximab: correlation between effector cells and clinical activity in NHL.
	<b>D162</b>	Juweid M. et al. <i>Cancer Res.</i> 55(23 Suppl.): 5827s-5831s, 1995. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
	<b>D163</b>	Juweid M. et al. <i>Cancer Res.</i> 55(23 Suppl.): 5899s-5907s, 1995. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody
	<b>D164</b>	Kaminski M. et al. <i>Antibody Immunoconj. Radiopharm.</i> 4(1): 36, abst. no. 66, 1991. Phase I trial results of <sup>131</sup> I antibody radioimmunotherapy (RAIT) of B-cell lymphoma.
	<b>D165</b>	Kaminski M.S. et al. <i>Antibody Immunoconj. Radiopharm.</i> 5(3): 345, abst. no. 57, 1992. Initial clinical radioimmunotherapy results with <sup>131</sup> I-anti-B1 (anti-CD20) in refractory B-cell lymphoma."
	<b>D166</b>	Kaminski M.S. et al. <i>Blood</i> 76(10 Suppl. 1): 355a, abst. no. 1409, 1990. Phase I evaluation of <sup>131</sup> I MB-1 antibody radioimmunotherapy (RIT) of B-cell lymphoma.
	<b>D167</b>	Kaminski M.S. et al. <i>Blood</i> 78(10 Suppl. 1): 43a, abst. no. 161, 1992. Radioimmunotherapy (RIT) of refractory B-cell lymphoma with <sup>131</sup> I-anti-B1 (anti-CD20) antibody: promising early results using non-marrow ablative radiation doses.
	<b>D168</b>	Kaminski M.S. et al. <i>J Clin. Oncol.</i> 14(7): 1974-81, 1996. Iodine- <sup>131</sup> I-anti-B1 radioimmunotherapy for B-cell lymphoma.
	<b>D169</b>	Kaminski M.S. et al. <i>N. Engl. J. Med.</i> 329: 459-65, 1993. Radioimmunotherapy of B-cell lymphoma with [ <sup>131</sup> I]anti-B1 (anti-CD20) antibody.
	<b>D170</b>	Kinoshita T. et al. <i>J. Clin. Oncol.</i> 16(12): 3916, Dec. 1998. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.
	<b>D171</b>	Klarnet J.P. et al. <i>J. Immunol.</i> 138(11): 4012-17, 1987. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory.
	<b>D172</b>	Knox S.J. et al. <i>Clin. Cancer Res.</i> 2: 457-70, 1996. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
	<b>D173</b>	Knox S.J. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 32: 215, 1995. <sup>90</sup> Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma.
	<b>D174</b>	Knox S.J. et al. <i>J. Immunother.</i> 16(2): 161, abst. no. 51, 1994. <sup>90</sup> Y-anti-CD20 monoclonal antibody therapy (IDEC-Y2B8) for recurrent B cell lymphoma.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 12 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D175</b>	Kuzel T. et al. <i>Cancer Biother.</i> 8(1): 3-16, 1993. A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.
	<b>D176</b>	Langmuir V.K. <i>Nucl. Med. Biol.</i> 19(2): 213-55, 1992. Radioimmunotherapy: clinical results and dosimetric considerations.
	<b>D177</b>	Larson S.M. et al. <i>Nucl. Med. Biol.</i> 16: 153-58, 1989. Comparison of bone marrow dosimetry and toxic effect of high dose <sup>131</sup> I-labeled monoclonal antibodies administered to man.
	<b>D178</b>	Lauria F. et al. <i>Bone Marrow Transplant.</i> 18(1): 79-85, 1996. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
	<b>D179</b>	Leichner P.K. et al. <i>Front. Rad. Ther. Oncol.</i> 24: 109-20, 1990. Dosimetry and treatment planning in radioimmunotherapy.
	<b>D180</b>	Leichner P.K. et al. <i>Med. Phys.</i> 20(2): 529-34, 1993. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles.
	<b>D181</b>	Levy R. et al. <i>Fed. Proc.</i> 42: 2650-56, 1983. Tumor therapy with monoclonal antibodies.
	<b>D182</b>	Ling N.R. et al. (in) <i>Leucocyte Typing III: White Cell Differentiation Antigens</i> , A.J. McMichael et al., eds., Oxford: Oxford Univ. Pr., 1987, pp. 302-35. B-cell and plasma cell antigens: new and previously defined clusters.
	<b>D183</b>	Link B.K. et al. <i>Proc. Ann. Mtg. ASCO</i> 17: 3a, abst. no. 7, 1998. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL.
	<b>D184</b>	Link M.P. et al. <i>J. Immunol.</i> 137(9): 3013-18, 1986. A unique antigen on mature B-cells defined by a monoclonal antibody.
	<b>D185</b>	Lipton J.M. et al. <i>Blood</i> 60(5 Suppl. 1): 170a, abst. no. 609, 1992. Distribution of B1, CALLA, $\beta$ 2 microglobulin and Ia on hematopoiesis supporting cells (HSC) in short and long-term cultures.
	<b>D186</b>	Lonberg N. et al. <i>Nature</i> 368: 856-59, 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications
	<b>D187</b>	Lowman H.B. Slides presented at IBC Antibody Engineering Conference, 2 December 2003. Differential activities in a series of humanized anti-CD20 antibodies.
	<b>D188</b>	Lum L.G. et al. <i>Blood</i> 69(2): 369-80, 1987. The kinetics of immune reconstitution after human marrow transplantation.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 13 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D189</b>	Macey D.J. et al. <i>Front. Rad. Ther. Oncol.</i> 24: 123-31, 1990. A treatment planning program for radioimmunotherapy.
	<b>D190</b>	Macklis R.M. et al. <i>Antibody Immunoconj. Radiother.</i> 5(3): abstr. no. 39, 1992. Induction of programmed cell death in malignant lymphomas after radioimmunotherapy.
	<b>D191</b>	Macklis R.M. et al. <i>Cancer</i> 73(3 Suppl.): 966-73, 1994. Radiobiologic studies of low-dose-rate <sup>90</sup> Y-lymphoma therapy.
	<b>D192</b>	Maloney D.G. et al. <i>Blood</i> 80(6): 1502-1510, 1992. Monoclonal anti-idiotypic antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells.
	<b>D193</b>	Maloney D.G. et al. <i>Blood</i> 88(10: Suppl. 1): 637a, abstr. no. 2635, 1996. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines.
	<b>D194</b>	Maloney D.M. et al. <i>Blood</i> 84(8): 2457-66, 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
	<b>D195</b>	Marquez S.D. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 39: 327, abstr. no. 2173, 1997. Hematological toxicity in radioimmunotherapy is predicted both by the computed absorbed whole body dose (cGy) and by the administered dose (mCi).
	<b>D196</b>	Marx J.L. <i>Science</i> 229(4712): 455-56, 1985. Antibodies made to order.
	<b>D197</b>	Masucci G. et al. <i>Med. Oncol. Tumor Pharmacother.</i> 8(3): 207-20, 1991. Chemotherapy and immunotherapy of colorectal cancer.
	<b>D198</b>	McLaughlin P. et al. <i>Blood</i> 92(10 Suppl. 1): 414a-415a, abstr. no. 1712, Nov. 1998. Efficacy controls and long-term follow-up for relapsed or refractory, low-grade or follicular (R-LG/F) NHL.
	<b>D199</b>	McLaughlin P. et al. <i>Oncology</i> 12(12): 1763-81, 1998. Clinical status and optimal use of rituximab for B-cell lymphomas.
	<b>D200</b>	Meredith R.F. et al. <i>J. Nucl. Med.</i> 33(9): 1648-53, 1992. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.
	<b>D201</b>	Mishell B.E. et al., eds. <i>Selected Methods in Cellular Immunology</i> , San Francisco: Freeman (1980), p. 287-304. Modification and use of antibodies to label cell surface antigens.
	<b>D202</b>	Morrison S. et al. <i>Proc. Nat'l Acad. Sci. USA</i> 81: 6851-54, 1984. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 14 OF 23</b>



<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No. 27693-01201	Serial No: <b>09/ 436,347</b>
	Inventor(s): Christine WHITE <i>et al.</i>	Examiner: A.M. HARRIS
	Filed: 9 November 1999	Art Unit: 1643

INITIAL	INDEX	CITATION
	<b>D203</b>	Morrison S.L. <i>Science</i> 229: 1202-07, 1985. Transfectomas provide novel chimeric antibodies.
	<b>D204</b>	Multani P.S. et al. <i>J. Clin. Oncol.</i> 16(11): 3691-3710, 1998. Monoclonal antibody-based therapies for hematologic malignancies.
	<b>D205</b>	Munro A. <i>Nature</i> 312: 597, 1984. Uses of chimeric antibodies.
	<b>D206</b>	Murray J.L. et al. <i>J. Biol. Resp. Modifiers</i> 9(6): 556-63, 1990. Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo.
	<b>D207</b>	Murray J.L. et al. <i>J. Nucl. Med.</i> 26: 3328-29, 1985. The effect of radionuclide dose on imaging with indium-111-labeled anti P-97 monoclonal antibody.
	<b>D208</b>	Muzaffar S. et al. <i>J. Pak. Med. Assn.</i> 47(4): 106-09, April 1997. Immunophenotypic analysis of non-Hodgkin's lymphoma.
	<b>D209</b>	Nadler L.M. et al. <i>Cancer Res.</i> 40(9): 3147-54, 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.
	<b>D210</b>	Nadler L.M. et al. <i>J. Clin. Invest.</i> 67: 134-140, 1981. A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
	<b>D211</b>	Nadler L.M. et al. <i>J. Clin. Invest.</i> 74(2): 332-40, 1984. B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation.
	<b>D212</b>	Nadler L.M. et al. <i>Lancet</i> 2(8400): 427-31, 1984. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma.
	<b>D213</b>	Nakamura K. et al. <i>Oncology</i> 50(1): 35-40, 1993. Effect of alpha-interferon on anti-alpha fetoprotein-monoclonal-antibody targeting of hepatoma.
	<b>D214</b>	Neuberger M.S. et al. <i>Nature</i> 314: 268-70, 1985. A hapten-specific chimaeric IgE antibody with human physiological effector function.
	<b>D215</b>	Nielsen B. et al. <i>Eur. J. Haematol.</i> 48(3): 146-51, 1992. Interferon- $\alpha$ -induced changes in surface antigens in a hairy-cell leukemia (JOK-1), and a Burkitt's lymphoma cell line (Daudi) during <i>in vitro</i> culture.
	<b>D216</b>	Non-Hodgkin's Lymphoma Pathologic Classification Project. <i>Cancer</i> 49(10): 2112-35, 1982. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas.
	<b>D217</b>	Oettgen H.C. et al. <i>Hybridoma</i> 2(1): 17-28, 1983. Further biochemical studies of the human B-cell differentiation antigens B1 and B2.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 15 OF 23</b>

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D218</b>	Oncology Nursing Society. <a href="http://onsopcontent.ons.org/oes/online_ce/lymph/.05-classification.htm">onsopcontent.ons.org/oes/online_ce/lymph/.05-classification.htm</a> , retrieved 25 February 2003. Current therapies and future directions in the treatment of non-Hodgkin's lymphoma.
	<b>D219</b>	Ozato K. et al. <i>J. Immunol.</i> 126(1): 317-21, 1981. Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression.
	<b>D220</b>	Parker B.A. et al. <i>Cancer Res.</i> 50(3): 1022s-1028s, 1990. Radioimmunotherapy of human B-cell lymphoma with <sup>90</sup> Y-conjugated antiidiotype monoclonal antibody.
	<b>D221</b>	Pearson J.W. et al. <i>Cancer Res.</i> 49(18): 4990-95, 1989. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice.
	<b>D222</b>	Petryk M. et al. <i>Oncologist</i> 6: 317-26, 2001. ASCO 2001: Critical commentaries: Hematologic malignancies.
	<b>D223</b>	Pietersz G.A. et al. <i>Immunol. Cell. Biol.</i> 65(2): 111-25, 1987. The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer.
	<b>D224</b>	Piro L.D. et al. <i>Ann. Oncol.</i> 10: 655-61, 1999. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
	<b>D225</b>	Polyak M.J. et al. <i>Blood</i> 99: 3256-62, 2002. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.
	<b>D226</b>	Press O. et al. <i>Proc. Ann. Mtg. ASCO</i> 5: 221, abst. no. 864, 1986. Serotherapy of malignant B cell lymphomas with monoclonal antibody 1F5 (anti-CD20).
	<b>D227</b>	Press O.W. <i>Cancer J. Sci. Amer.</i> 4(Suppl 2): S19-S26, Jul. 1998. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates.
	<b>D228</b>	Press O.W. et al. <i>Adv. Exp. Med. Biol.</i> 303: 91-96, 1991. Radiolabeled antibody therapy of human b cell lymphomas.
	<b>D229</b>	Press O.W. et al. <i>Blood</i> 69(2): 584-91, 1987. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.
	<b>D230</b>	Press O.W. et al. <i>Cancer Res.</i> 49(17): 4906-12, 1989. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 16 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D231</b>	Press O.W. et al. <i>J. Clin. Oncol.</i> 7(8): 1027-38, 1989. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
	<b>D232</b>	Press O.W. et al. <i>Lancet</i> 346(8971): 336-40, 1995. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.
	<b>D233</b>	Press O.W. et al. <i>N. Engl. J. Med.</i> 329(17): 1219-23, 1993. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
	<b>D234</b>	Press O.W. et al. <i>Proc. Ann. Mtg. ASCO</i> 17, abst. no. 9, May 1998. A phase I/II trial of high dose iodine-131-anti-B1 (anti-CD20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphomas.
	<b>D235</b>	Reff M. et al. <i>J. Cell. Biochem. Suppl.</i> 17E: 260, abst. no. T103, 1993. Depletion of B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20.
	<b>D236</b>	Reff M.E. et al. <i>Blood</i> 83(2): 435-45, 1994. Depletion of B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20.
	<b>D237</b>	Reilly R.M. <i>Clin. Pharm.</i> 10: 359-75, 1991. Radioimmunotherapy of malignancies.
	<b>D238</b>	Rottenburger C. et al. <i>Br. J. Haematol.</i> 106(2): 545-52, 1999. Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation.
	<b>D239</b>	Sahagan B.G. et al. <i>J. Immunol.</i> 137: 1066-74, 1986. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen.
	<b>D240</b>	Scharff M. <i>Harvey Lectures</i> 69: 125-42, 1974. The synthesis, assembly, and secretion of immunoglobulin: a biochemical and genetic approach.
	<b>D241</b>	Schlom J. et al. <i>J. Natl. Cancer Inst.</i> 82(9): 763-71, 1990. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy.
	<b>D242</b>	Schwartz-Albiez R. et al. <i>J. Immunol.</i> 140(3): 905-14, 1988. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein.
	<b>D243</b>	See-Lasley K. et al. <i>Manual of Oncology Therapeutics</i> . St. Louis: C.V. Mosby Co., pages 44-71, 1981. Hodgkin's disease and non-Hodgkin's lymphoma.
	<b>D244</b>	Senter P.D. <i>FASEB J.</i> 4: 188-93, 1990. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy.
	<b>D245</b>	Senter P.D. et al. <i>Adv. Exp. Med. Biol.</i> 303: 97-105, 1991. Activation of prodrugs by antibody-enzyme conjugates.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 17 OF 23</b>

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D246</b>	Senter P.D. et al. <i>Cancer Res.</i> 49: 5789-92, 1989. Enhancement of the <i>in vitro</i> and <i>in vivo</i> antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates.
	<b>D247</b>	Shan D. et al. <i>Clin. Cancer Res.</i> 7(8): 2490-95, 2001. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.
	<b>D248</b>	Sharkey R.M. et al. <i>Cancer Res.</i> 50(3): 964s-969s, 1990. Biological considerations for radioimmunotherapy.
	<b>D249</b>	Shulman M. et al. <i>Nature</i> 276(5685): 269-72, 1978. A better cell line for making hybridomas secreting specific antibodies.
	<b>D250</b>	Smalley R.V. et al. <i>N. Engl. J. Med.</i> 327(19): 1336-41, 1992. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.
	<b>D251</b>	Smeland E.B. et al. <i>J. Immunol.</i> 138(10): 3179-84, 1987. Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells.
	<b>D252</b>	Soiffer R.J. et al. <i>Blood</i> 79(2): 517-26, 1992. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
	<b>D253</b>	Soiffer R.J. et al. <i>Blood</i> 84(3): 964-971, 1994. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation.
	<b>D254</b>	Solal-Celigny P. et al. <i>J. Clin. Oncol.</i> 16(7): 2332-38, 1998. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.
	<b>D255</b>	Srivastava S.C. et al. <i>Nucl. Med. Biol. (I.J. Rad. Appl. Instrum. B)</i> 18(6): 589-603, 1991. Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies.
	<b>D256</b>	Stashenko P. et al. <i>J. Immunol.</i> 125(4): 1678-85, 1980. Characterization of Human B Lymphocyte-Specific Antigen.
	<b>D257</b>	Staudt L.M. et al. Manuscript from pubmedcentral at NIH, edited paper published at <i>Adv. Immunol.</i> 87: 163-208, 2005. The biology of human lymphoid malignancies revealed by gene expression profiling.
	<b>D258</b>	Stewart J.S.W. et al. <i>Int. J. Cancer Suppl.</i> 3: 71-76, 1988. Intraperitoneal <sup>131</sup> I- And <sup>90</sup> Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 18 OF 23</b>

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D259</b>	Sun L.K. et al. <i>Hybridoma</i> 5(Suppl. 1): S17-20, 1986. Chimeric antibodies with 17-1A-derived variable and human constant regions.
	<b>D260</b>	Tan L.K. et al. <i>J. Immunol.</i> 135: 3564-67, 1985. A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells.
	<b>D261</b>	Tedder T.F. et al. <i>Eur J. Immunol.</i> 16(8): 881-87, 1986. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes.
	<b>D262</b>	Tedder T.F. et al. <i>J. Immunol.</i> 135(2): 973-79, 1985. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.
	<b>D263</b>	Tedder T.F. et al. <i>J. Immunol.</i> 141(12): 4388-94, 1988. Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19.
	<b>D264</b>	Teeling J.L. et al. <i>Blood</i> 104:1793-1800, 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
	<b>D265</b>	Teeling J.L. et al. <i>J. Immunol.</i> 277: 362-71, 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.
	<b>D266</b>	Tobinai K. et al. <i>Ann. Oncol.</i> 9(5): 527-34, 1998. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
	<b>D267</b>	Tsai D.E. et al. <i>Blood</i> 92(10 Suppl. 1): 415a, abst. no. 1713, Nov. 1998. Progressive intermediate grade non-Hodgkin's lymphoma after high dose therapy and autologous peripheral stem cell transplantation (PSCT) has a high response rate to rituximab.
	<b>D268</b>	Tsai D.E. et al. <i>Bone Marrow Transplant.</i> 24(5): 521-26, 1999. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation
	<b>D269</b>	Tsai D.E. et al. <i>Clin. Lymphoma Myeloma</i> 1(1): 62-66, 2000. Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy.
	<b>D270</b>	Uckun F.M. et al. <i>Cancer Res.</i> 45(1): 69-75, 1985. Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein.
	<b>D271</b>	Uckun F.M. et al. <i>J. Immunol.</i> 134(5): 3504-15, 1985. Combined <i>ex vivo</i> treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 19 OF 23</b>

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D272</b>	Urlaub, G. et al. <i>Som. Cell. Mol. Genet.</i> 12(6): 555-66, 1986. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions.
	<b>D273</b>	Valentine M.A. et al. <i>J. Biol. Chem.</i> 264: 11282-87, 1989. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C.
	<b>D274</b>	van der Kolk L.E. et al. <i>Blood</i> 92(10 Suppl. 1): 241b, abst. no. 4037, Nov. 1998. Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B-cell lymphoma: a phase I/II clinical trial.
	<b>D275</b>	van der Kolk L.E. et al. <i>Br. J. Haematol.</i> 102(1): 243, abst. no. P-0970, Jul. 1998. Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B-cell lymphoma: a phase I/II clinical trial.
	<b>D276</b>	Venugopal P. et al. <i>Blood</i> 92(10 Suppl. 1): 247a, abst. no. 1009, Nov. 1998. Upregulation of CD20 expression in chronic lymphocytic leukemia (CLL) cells by in vitro exposure to cytokines.
	<b>D277</b>	Verkh L.I. et al. <i>Proc. Ann. Mtg. ASCO</i> 17: abst. no. 154, 1998. Dosimetry results of ONCOLYM™ in the treatment of refractory B cell non-Hodgkin's lymphoma (NHL).
	<b>D278</b>	Vey N. et al. <i>Leuk. Lymphoma</i> 221(1-2): 107-14, 1996. A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas.
	<b>D279</b>	Vose J.M. et al. <i>J. Clin. Oncol.</i> 19(2): 389-97, 2001. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
	<b>D280</b>	Wadler S. et al. <i>Semin. Oncol.</i> 19(2 Suppl. 3): 45-48, 1992. Principles in the biomodulation of cytotoxic drugs by interferons.
	<b>D281</b>	Wahl R.L. et al. <i>Proc. Ann. Mtg. ASCO</i> 17: 40a, abst. no. 156, May 1998. Successful re-treatment of non-Hodgkin's lymphoma (NHL) with iodine-131 anti-B1 antibody.
	<b>D282</b>	Welte K. et al. <i>Blood</i> 64: 380-85, 1984. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2.
	<b>D283</b>	Wessels B.W. et al. <i>Med. Phys.</i> 11(5): 638-45, 1984. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.
	<b>D284</b>	White C.A. et al. <i>Ann. Oncol.</i> 10(3 Suppl): 64, abst. no. 215, 1999. Radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma (NHL): IDEC-Y2B8 phase I/II <sup>90</sup> yttrium trial.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 20 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D285</b>	White C.A. et al. <i>Ann. Rev. Med.</i> 52: 125-45, 2001. Antibody-targeted immunotherapy for treatment of malignancy.
	<b>D286</b>	White C.A. et al. <i>Blood</i> 87(9): 3640-49, 1996. Radioimmunotherapy of relapsed B-cell lymphoma with Yttrium 90 anti-idiotypic monoclonal antibodies.
	<b>D287</b>	White C.A. et al. <i>Eur. J. Cancer</i> 35: S57, abst. no. 107, 1999. Zevalin™ radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma.
	<b>D288</b>	Winkler U. et al. <i>Blood</i> 92(10 Suppl. 1): 285b, abst. no. 4228, Nov. 1998. Severe side effects in patients with B-cell chronic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab.
	<b>D289</b>	Wiseman G. et al. <i>Blood</i> 92(10 Suppl. 1): 417a, abst. no. 1721, Nov. 1998. IDEC-Y2B8 radioimmunotherapy: baseline bone marrow involvement and platelet count are better predictors of hematologic toxicity than dosimetry.
	<b>D290</b>	Wiseman G. et al. <i>Cancer Biother. Radiopharm.</i> 13(1): 59, abst. no. 22, 1998. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 <sup>90</sup> yttrium anti-CD20 monoclonal antibody.
	<b>D291</b>	Wiseman G. et al. <i>Cancer Biother. Radiopharm.</i> 13(4): 317, abst. no. 51, 1998. IDEC-Y2B8 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim analysis.
	<b>D292</b>	Wiseman G. et al. <i>Cancer Biother. Radiopharm.</i> 14(4): 315, abst. no. 2, 1999. <sup>90</sup> Yttrium labelled IDEC Y2B8 anti-CD20 radioimmunotherapy.
	<b>D293</b>	Wiseman G. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 45(10 Suppl): 390, abst. no. 260, 1999. Radioimmunotherapy of relapsed or refractory non-Hodgkin's Lymphoma (NHL) with IDEC-Y2B8.
	<b>D294</b>	Wiseman G. et al. <i>Proc. Ann. Mtg. ASCO</i> 17, 1998. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 <sup>90</sup> yttrium radioimmunotherapy.
	<b>D295</b>	Wiseman G.A. et al. <i>Blood</i> 92(10 Suppl. 1): 510a, abst. no. 2273, Nov. 1998. IDEC-Y2B8 ( <sup>90</sup> Y conjugated anti-CD20) dosimetry calculated from <sup>111</sup> In anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma (NHL) emphasis on bone marrow (BM).
	<b>D296</b>	Wiseman G.A. et al. <i>Blood</i> 94(10 Suppl. 1): 92a, abst. no. 403, 1999. ZEVALIN™ biodistribution and dosimetry estimated normal organ absorbed radiation doses are not affected by prior therapy with rituximab.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 21 OF 23	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D297</b>	Wiseman G.A. <i>et al.</i> <i>Clin. Cancer Res.</i> 5(Suppl.): 3281s-3286s, 1999. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a <sup>90</sup> Y-labeled anti-CD20 monoclonal antibody.
	<b>D298</b>	Wiseman G.A. <i>et al.</i> <i>I.J. Oncol. Biol. Phys.</i> 42(1 Suppl.): 130, abst. no. 11, 1998. IDEC-Y2B8 ( <sup>90</sup> yttrium ibritumomab tiuxetan) radioimmunotherapy safety results in relapsed or chemotherapy refractory non-Hodgkin's lymphoma patients treated at reduced doses because of pre-existing thrombocytopenia.
	<b>D299</b>	Wiseman G.A. <i>et al.</i> <i>J. Nucl. Med.</i> 38(5 Suppl.): 251, abst. no. 1062, 1997. Y-90 anti-CD20 monoclonal antibody (IDEC-Y2B8) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma.
	<b>D300</b>	Wiseman G.A. <i>et al.</i> <i>J. Nucl. Med.</i> 39(5 Suppl.): 185P, abst. no. 836, 1998. Whole-body gamma camera image quantification from multiple camera types for radioisotope therapy dosimetry.
	<b>D301</b>	Wiseman G.A. <i>et al.</i> <i>J. Nucl. Med.</i> 39(5 Suppl.): 69P, abst. no. 267, 1998. Non-Hodgkin's lymphoma tumor and bone marrow radiation doses from radioimmunotherapy with IDEC-Y2B8 yttrium-90 anti-CD20 monoclonal antibody.
	<b>D302</b>	Wiseman G.A. <i>et al.</i> <i>J. Nucl. Med.</i> 40(1 Suppl.): 64P, abst. no. 260, 1999. Final dosimetry results of IDEC-Y2B8 phase I/II <sup>90</sup> yttrium radioimmunotherapy trial in non-Hodgkin's lymphoma (NHL).
	<b>D303</b>	Wiseman G.A. <i>et al.</i> <i>Proc. Ann. Mtg. ASCO</i> 18: 4a, abst. no. 13, 1999. Therapeutic index of IDEC-Y2B8 radioimmunotherapy: up to 850 fold greater radiation dose to tumor than normal organs.
	<b>D304</b>	Witherspoon R.P. <i>et al.</i> <i>Semin. Hematol.</i> 21(1): 2-10, 1984. Immunologic reconstitution after human marrow grafting.
	<b>D305</b>	Witzig T. <i>et al.</i> <i>Blood</i> 90(10 Suppl. 1): 586a, abst. no. 2606, 1997. IDEC-Y2B8 <sup>90</sup> yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim results of a phase I/II trial.
	<b>D306</b>	Witzig T. <i>et al.</i> <i>Blood</i> 92(10 Suppl. 1): 417a, abst. no. 1722, Nov. 1998. IDEC-Y2B8 radioimmunotherapy: responses in patients with splenomegaly.
	<b>D307</b>	Witzig T.E. <i>et al.</i> <i>Blood</i> 94(10 Suppl. 1): 92a, abst. no. 400, 1999. Reduced-dose ZEVALIN <sup>TM</sup> radioimmunotherapy for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) patients with pre-existing thrombocytopenia: report of interim results of a phase II trial.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 22 OF 23</b>



<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	<b>D308</b>	Witzig T.E. et al. <i>J. Clin. Oncol.</i> 17(12): 3793-3803, 1999. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
	<b>D309</b>	Witzig T.E. et al. <i>J. Clin. Oncol.</i> 20: 2453-63, 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
	<b>D310</b>	Witzig T.E. et al. <i>J. Clin. Oncol.</i> 20(15): 3262-69, 2002. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
	<b>D311</b>	Witzig T.E. et al. <i>J. Immunother.</i> 21(6): 463, abst. no. 2805, 1998. IDEC-Y2B8 radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma.
	<b>D312</b>	Witzig T.E. et al. <i>Proc. Ann. Mtg. ASCO</i> 18: 41a, abst. no. 152, 1999. Commonly used response criteria for non-Hodgkin's lymphoma (NHL) applied to IDEC-Y2B8 radioimmunotherapy trial: importance of "normal" lymph node size.
	<b>D313</b>	Witzig T.E. et al. <i>Blood</i> 94(10 Suppl. 1): 631a, abst. no. 2805, 1999. Prospective randomized controlled study of ZEVALIN™ (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results.
	<b>D314</b>	Yang H. et al. <i>Am. J. Hematol.</i> 62: 247-50, 1999. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
	<b>D315</b>	Yokota S. et al. <i>Cancer Res.</i> 50: 32-37, 1990. Synergistic potentiation of <i>in vivo</i> antitumor activity of anti-human T-leukemia immunotoxins by recombinant $\alpha$ -interferon and daunorubicin.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	
<b>SHEET 23 OF 23</b>	